BIBP 3226 trifluoroacetate: Precision Antagonist for NPY/NPFF System Research

Executive Summary: BIBP 3226 trifluoroacetate (SKU B7155) is a non-peptide antagonist with nanomolar affinity for the NPY Y1 and NPFF receptor subtypes, validated in both rodent and human models (Fan et al., 2024). It blocks NPFF-induced inhibition of cAMP and antagonizes NPFF-dependent physiological effects in vivo (APExBIO). Recent stem cell-based coculture models implicate the NPY/Y1R axis as a critical mediator in cardiac arrhythmias, positioning BIBP 3226 as a strategic probe (Fan et al., 2024). The compound offers solubility across DMSO, ethanol, and water (with sonication), and is supplied at >98% purity with full analytical QC. Its use is strictly for research; it is not intended for diagnostic or clinical therapeutics (APExBIO).

Biological Rationale

Neuropeptide Y (NPY) and neuropeptide FF (NPFF) are key neuromodulators in the central and peripheral nervous systems. They regulate anxiety, pain, and cardiovascular homeostasis (Fan et al., 2024). The NPY/NPFF system is implicated in the adipose-neural axis, which influences cardiac arrhythmias by modulating sympathetic activity and myocardial electrophysiology. In recent studies, elevated NPY and leptin levels in epicardial adipose tissue (EAT) and coronary sinus blood were correlated with atrial fibrillation (Fan et al., 2024). Blocking the Y1 receptor (Y1R) attenuates these arrhythmic phenotypes in stem cell-based coculture models, indicating a causal neuropeptide pathway. BIBP 3226 trifluoroacetate, as a selective Y1R/NPFF antagonist, enables precise interrogation of these mechanisms (Binding-Buffer.com). This article clarifies the translational significance and usage parameters of BIBP 3226 trifluoroacetate beyond prior scenario guides.

Mechanism of Action of BIBP 3226 trifluoroacetate

BIBP 3226 trifluoroacetate acts as a non-peptide antagonist at the NPY Y1 and NPFF receptors. It binds with a Ki of 1.1 nM for rat NPY Y1, 79 nM for human NPFF2, and 108 nM for rat NPFF receptors (APExBIO). The compound competitively inhibits endogenous NPFF and NPY ligands, preventing their downstream signaling. In cellular assays, BIBP 3226 blocks NPFF-induced inhibition of forskolin-stimulated cAMP production, a key second-messenger pathway in neuropeptide signaling. In vivo, it blocks NPFF-dependent hypothermia and anti-opioid effects in rodents, confirming target engagement. In cardiac models, BIBP 3226 antagonizes NPY/Y1R-mediated activation of the Na+/Ca2+ exchanger (NCX) and CaMKII, interrupting arrhythmogenic signaling (Fan et al., 2024). This multi-receptor selectivity distinguishes BIBP 3226 from peptide-based antagonists with limited bioavailability or specificity (Angiotensin-1-2-a-2-8.com). This mechanism updates prior guides by integrating recent coculture model findings.

Evidence & Benchmarks

• BIBP 3226 trifluoroacetate exhibits high binding affinity (Ki = 1.1 nM) for rat NPY Y1 receptors, supporting its use as a benchmark antagonist (APExBIO).
• In coculture models, Y1R antagonism by BIBP 3226 blocks arrhythmogenic signaling induced by leptin/NPY, directly implicating the NPY/Y1 axis in cardiac arrhythmia (Fan et al., 2024).
• BIBP 3226 demonstrates robust antagonism in cAMP signaling assays, preventing NPFF-induced pathway inhibition in vitro under forskolin stimulation conditions (APExBIO).
• Cardiac arrhythmia models show that Y1R blockade reduces abnormal CaMKII and NCX activity, a critical mechanistic insight for cardiovascular research (Fan et al., 2024).
• The product is supplied at >98% purity, with full HPLC, MS, and NMR validation, ensuring reproducibility and data integrity (APExBIO).

For additional context on real-world deployment, see the application-focused scenario guide (Sulisobenzonechem.com), which this article extends by mapping to recent arrhythmia targets and clarifying mechanistic endpoints.

Applications, Limits & Misconceptions

BIBP 3226 trifluoroacetate is deployed in:

• Dissecting NPY/NPFF pathways in anxiety, analgesia, and cardiovascular models.
• Cellular assays for cAMP signaling, viability, proliferation, and cytotoxicity.
• Advanced coculture systems modeling neuro-adipose-cardiac interactions.

Its specificity and solubility profile make it suitable for both in vitro and ex vivo studies. However, it is not approved for diagnostic or therapeutic use. Its antagonism is selective for Y1 and NPFF receptors but does not block all NPY or opioid receptor subtypes. Use in solution requires prompt application due to stability constraints.

Common Pitfalls or Misconceptions

• BIBP 3226 trifluoroacetate does not antagonize all NPY receptor subtypes (e.g., Y2, Y5); its selectivity is for Y1 and NPFF receptors (APExBIO).
• It is not a direct ion channel blocker; its effects on CaMKII and NCX are indirect via neuropeptide signaling (Fan et al., 2024).
• The compound is not intended for in vivo diagnostic or clinical use; research-only designation applies (APExBIO).
• Long-term solutions are unstable; use preparations promptly to avoid loss of activity.
• Solubility in water requires ultrasonic assistance; incomplete dissolution may lead to inconsistent dosing.

This article clarifies mechanistic boundaries and workflow best-practices beyond the broader overviews in Peptide-YY.com.

Workflow Integration & Parameters

• Solubility: ≥78 mg/mL in DMSO, ≥73.2 mg/mL in ethanol, ≥12.13 mg/mL in water with sonication (APExBIO).
• Storage: Store powder at -20°C; avoid repeated freeze-thaw cycles.
• Stability: Solutions are unstable long-term; prepare fresh aliquots for each experiment.
• QC: Supplied with HPLC, MS, NMR, COA; purity >98%.
• Application: Suitable for cell-based screening, signaling assays, and mechanistic studies in coculture systems.

For advanced experimental design integrating BIBP 3226 trifluoroacetate into coculture and signal transduction studies, see Peptide-YY.com, which this article updates by incorporating recent arrhythmia model evidence.

Conclusion & Outlook

BIBP 3226 trifluoroacetate, provided by APExBIO, is a rigorously characterized, selective antagonist for the NPY/NPFF receptor pathways. Its validated performance in high-fidelity mechanistic assays, especially those modeling neuro-adipose-cardiac interactions, positions it as a reference standard for anxiety, analgesia, and cardiovascular regulation research. Ongoing advancements in stem cell-based coculture models and signal pathway mapping further expand the utility of BIBP 3226 trifluoroacetate in translational discovery. For ordering and technical details, refer to the product page.